Daily Orange Consumption Reduces Hepatic Steatosis Prevalence in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Exploratory Outcomes of a Randomized Clinical Trial

• Published in: Nutrients Vol. 16; no. 18; p. 3191
• Main Authors: Notarnicola, Maria, Tutino, Valeria, De Nunzio, Valentina, Cisternino, Anna Maria, Cofano, Miriam, Donghia, Rossella, Giannuzzi, Vito, Zappimbulso, Marianna, Milella, Rosa Anna, Giannelli, Gianluigi, Fontana, Luigi
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.09.2024; MDPI
• Subjects: Adult; Aged; Agricultural research; Antioxidants; Atherosclerosis; Body fat; Body mass index; Body weight; CAP; Cholesterol; Chromatography; Citrus; Citrus fruits; Citrus sinensis; Clinical trials; Diabetes; Diabetes therapy; Diet; Elasticity Imaging Techniques; Enzymes; Ethylenediaminetetraacetic acid; Exercise; Fatty acids; Fatty Liver - epidemiology; Fatty Liver - etiology; Female; Flavonoids; Fruit; Fruit and Vegetable Juices; Gastroenterology; Humans; Insulin resistance; Isoflavones; Lipids; Liver - metabolism; Liver - pathology; Liver diseases; Male; MASLD; Metabolism; Middle Aged; Non-alcoholic Fatty Liver Disease - epidemiology; Non-alcoholic Fatty Liver Disease - etiology; Nutrition research; Obesity; oranges; Overweight; Oxidation; Patient outcomes; phytochemical food; Prevalence; steatosis; Triglycerides; Type 2 diabetes; Weight control; Palo Alto California; United States > US; Italy; CAP; oranges; phytochemical food; MASLD; steatosis
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu16183191

: Consumption of flavonoid-rich orange juice has been shown to reduce adiposity and liver steatosis in murine models of diet-induced obesity. However, little is known about the effects of whole orange intake, independent of body weight changes, on liver function and steatosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The goal is to understand the direct impact of orange consumption on metabolic health. : Sixty-two men and women aged 30-65 with MASLD (Controlled Attenuation Parameter, (CAP) > 275 dB/m) were randomly assigned to consume either 400 g of whole oranges or non-citrus fruits daily for 4 weeks. Baseline evaluations included medical assessments, blood tests, and body composition. Liver health was assessed using transient elastography (FibroScan ) for steatosis and fibrosis, conducted by blinded personnel. This clinical trial was registered at ClinicalTrials.gov (NCT05558592). : After 4 weeks of orange supplementation, liver steatosis decreased in the treatment group, with 70.9% showing steatosis compared to 100% in controls ( < 0.004), indicating a 30% reduction in liver disease prevalence. There were no significant changes in fibrosis or plasma liver enzymes, though plasma gamma glutaril transferase (GGT) levels decreased significantly. Body weight, waist circumference, body composition, lipid profile, fasting glucose, insulin, and C-reactive protein levels remained unchanged. Dietary analysis revealed no change in caloric intake, but vitamins C, A, thiamine, and riboflavin increased in the orange group. : Our findings suggest that phytochemical-rich foods, especially whole fruits like oranges, may enhance liver function as an adjunct treatment for MASLD. The notable reduction in liver steatosis prevalence occurred independently of body weight changes. Further studies are needed to investigate the long-term effects of orange supplementation on steatosis and fibrosis progression and to identify the specific bioactive compounds and mechanisms involved.